Applied DNA Sciences IncNASDAQ:APDNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.3700
- TODAY'S CHANGE (%)-0.6300 (-12.6000%)
- Bid / Lots4.1600/ 2
- Ask / Lots4.5500/ 1
- Open / Previous Close4.8100 / 5.0000
- Day Range
- 52 Week Range
- Volume84,024
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APDN |
|---|---|---|
| 09:32 ET | 1613 | 4.8001 |
| 09:34 ET | 100 | 4.8742 |
| 09:38 ET | 318 | 4.82 |
| 09:39 ET | 1830 | 4.71 |
| 09:41 ET | 287 | 4.71 |
| 09:43 ET | 500 | 4.64 |
| 09:45 ET | 2280 | 4.58 |
| 09:48 ET | 400 | 4.64 |
| 09:57 ET | 400 | 4.59 |
| 10:01 ET | 737 | 4.59 |
| 10:10 ET | 100 | 4.65 |
| 10:12 ET | 550 | 4.65 |
| 10:26 ET | 4300 | 4.7 |
| 10:28 ET | 1860 | 4.65 |
| 10:30 ET | 294 | 4.62 |
| 10:51 ET | 300 | 4.62 |
| 10:53 ET | 100 | 4.6305 |
| 10:57 ET | 2396 | 4.6183 |
| 11:22 ET | 500 | 4.64 |
| 11:24 ET | 7156 | 4.5 |
| 11:29 ET | 200 | 4.6 |
| 11:47 ET | 200 | 4.5 |
| 11:56 ET | 295 | 4.5153 |
| 12:02 ET | 100 | 4.55 |
| 12:05 ET | 600 | 4.57 |
| 12:39 ET | 200 | 4.57 |
| 12:41 ET | 100 | 4.57 |
| 12:43 ET | 200 | 4.51 |
| 12:45 ET | 1876 | 4.44 |
| 12:48 ET | 100 | 4.4145 |
| 12:59 ET | 100 | 4.36 |
| 01:03 ET | 100 | 4.35 |
| 01:08 ET | 858 | 4.3 |
| 01:14 ET | 330 | 4.2332 |
| 01:19 ET | 5562 | 4.3501 |
| 01:21 ET | 4126 | 4.45 |
| 01:32 ET | 100 | 4.5735 |
| 01:33 ET | 390 | 4.55 |
| 02:09 ET | 100 | 4.4501 |
| 02:26 ET | 800 | 4.545 |
| 02:49 ET | 132 | 4.5775 |
| 02:58 ET | 3455 | 4.64 |
| 03:05 ET | 103 | 4.62 |
| 03:27 ET | 100 | 4.51 |
| 03:32 ET | 100 | 4.49 |
| 03:36 ET | 2040 | 4.15 |
| 03:38 ET | 100 | 4.12 |
| 03:41 ET | 2521 | 4.42 |
| 03:43 ET | 1250 | 4.36 |
| 03:45 ET | 1929 | 4.25 |
| 03:48 ET | 500 | 4.1999 |
| 03:54 ET | 8791 | 4.33 |
| 03:56 ET | 1332 | 4.26 |
| 03:57 ET | 600 | 4.41 |
| 03:59 ET | 557 | 4.37 |
Yesterday
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program, from 9:30AM ET on Thursday Apr 25, 2024 by Dow Jones
9:30AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 22, 2024
Applied DNA Announces 1-For-20 Reverse Stock Split, from 4:06PM ET on Monday Apr 22, 2024 by Dow Jones
4:06PM ET on Monday Apr 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Applied DNA Sciences Inc | 4.3M | -8.0x | --- |
Vivos Therapeutics Inc | 6.7M | -0.2x | --- |
Encision Inc | 5.2M | -11.6x | --- |
Acutus Medical Inc | 4.9M | -0.4x | --- |
Fuse Medical Inc | 7.3M | 2.7x | +2.06% |
Lancer Orthodontics Inc | 4.2K | 0.0x | -9.28% |
Company Information
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Contact Information
- Headquarters
- 50 Health Sciences DriveSTONY BROOK, NY, United States 11790
- Phone
- 631-240-8800
- Fax
- 631-240-8900
Executives
- Chairman of the Board, President, Chief Executive Officer
- James Hayward
- Chief Financial Officer
- Beth Jantzen
- Chief Operating Officer, Chief Information Officer, Secretary
- Judith Murrah
- Chief Legal Officer, Executive Director - Business Development
- Clay Shorrock
- Independent Director
- Robert Catell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3M |
|---|---|
Revenue (TTM) | $9.0M |
Shares Outstanding | 863.0K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.21 |
EPS | $-0.55 |
Book Value | $0.36 |
P/E Ratio | -8.0x |
Price/Sales (TTM) | 0.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -150.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
